Quick Answer
Harmony Biosciences Holdings, Inc. reported Stockholders Equity of $870.22 million for the year ending 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +32.0% in Stockholders Equity from 2024 to 2025.
- This data is from Harmony Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$343.63 million | Q3 2019: -$384.91 million | Q1 2020: -$472.33 million | Q2 2020: -$483.36 million | Q3 2020: $94.55 million | Q1 2021: $107.88 million | Q2 2021: $126.55 million | Q3 2021: $152.02 million | Q1 2022: $214.50 million | Q2 2022: $246.53 million | Q3 2022: $343.88 million | Q1 2023: $443.04 million | Q2 2023: $485.17 million | Q3 2023: $481.33 million | Q1 2024: $515.39 million | Q2 2024: $538.58 million | Q3 2024: $596.80 million | Q1 2025: $720.53 million | Q2 2025: $773.08 million | Q3 2025: $835.12 million.
- Over the full 8 years of available data (2018 to 2025), Harmony Biosciences Holdings, Inc.'s Stockholders Equity has grown by 458.6%.
- Historical annual values: Fiscal year 2025: $870.22 million | Fiscal year 2024: $659.16 million | Fiscal year 2023: $466.99 million | Fiscal year 2022: $402.84 million | Fiscal year 2021: $186.51 million | Fiscal year 2020: $97.18 million | Fiscal year 2019: -$422.86 million | Fiscal year 2018: -$242.67 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: